Session Information
AABB Annual Meeting and CTTXPO 2010
Click here to go to the previous page
Mouse Models in Transfusion Medicine: Hematological Disorders
Track
:
S- Scientific
Program Code:
9306-S
Date:
Monday, October 11, 2010
Time:
10:30 AM to 12:00 PM
EST
Location:
327/328
DIRECTOR
:
Steven Spitalnik, MD, Professor, Columbia University
MODERATOR
:
Steven Spitalnik, MD, Professor, Columbia University
SPEAKER
(S):
Steven Spitalnik, MD, Professor, Columbia University
Jeffrey Jhang, MD, Associate Professor of Clinical Pathology and Cell Biology, College of Physicians and Surgeons of Columbia University
Dr. Don Siegel, MD, PhD, Director, Division of Transfusion Medicine & Therapeutic Pathology, Department of Pathology, University of Pennsylvania
Yelena Ginzburg, MD, Medical Director, Special Patient Services; Assistant Member, Lindsley F. Kimball Research Institute - PI, Erythropoiesis Laboratory, New York Blood Center
Description
The overall goal of this session is to discuss how the use of mouse models can improve our understanding of human diseases relevant to the transfusion medicine community because of the use of coagulation factors (i.e. in von Willebrand's disease), therapeutic apheresis (i.e. in thrombotic thrombocytopenic purpura), and chronic RBC transfusion therapy (i.e. in beta-thalassemia). To this end, short lectures on the following three topics will be provided by investigators currently working with these mouse models:
mouse models of von Willebrand disease: Insights into platelet adhesion and von Willebrand factor function,
use of mouse models to study the role ADAMTS13 plays in thrombotic disorders, and
mouse models of beta-thalassemia.
mouse models of von Willebrand disease: Insights into platelet adhesion and von Willebrand factor function,
use of mouse models to study the role ADAMTS13 plays in thrombotic disorders, and
mouse models of beta-thalassemia.
- Describe the roles of ADAMTS13, and inhibitors thereof, in the pathogenesis of human thrombotic disorders.
- Discuss the roles of von Willebrand factor in normal platelet function and in the pathogenesis of human bleeding disorders.
- Explain the pathogenesis of beta-thalassemia and the effects of iron overload in this disorder of ineffective erythropoiesis.
| CE Category | CE Value |
|---|---|
| California Clinical Laboratory Personnel | 1.5 |
| California Nurse | 1.8 |
| Florida Laboratory Personnel | 1.8 |
| General Attendee | 1.5 |
| Physician | 1.5 |
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.
This session is a part of:
Online Access
(Code: 9306-S)
Attendee/Member:$25 USD
Attendee:$40 USD
Member:$40 USD
Non-Attendee/Non-Member $50 USD - Your Price
This session is a part of:
 | Copyright © 2014 by MultiView, Inc. All website graphics, text, design, software, and other works are the copyrighted works of MultiView, Inc. All audio, video, presentation materials, logos and text are the copyrighted works of their respective owners. All Rights Reserved. Any redistribution or reproduction of any materials herein is strictly prohibited. |  |